This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS Primary aims: Determine the 6-month progression-free survival rate for patients with recurrent or progressive glioblastoma treated with GW572016. Determine whether GW572016 inhibits the phosphorylation of its cellular targets EGFR and HER2, and the downstream PI3K-AKT and RAS-ERK signaling pathways in glioblastoma patients in vivo. Determine tumor concentrations of GW572016.Secondary aims: Overall progression free survival.
Showing the most recent 10 out of 1085 publications